Frontera Therapeutics
Edit info- Founded: 2019
- Location: Bedford, MA
- Employee range: 50 - 200
- Clinical stage: Clin1
- Therapy area: wAMD
- Drug types: OPH, RAR, HEM, END, CVV, NEU
- Lead product: FT-003
- Funding: $160M B Jul 2022
- Investors: OrbiMed, Boyu Capital Consultancy, Sequoia China, Creacion Ventures
fronteratherapeutics.com linkedin.com job board
Drug notes:
FT-001 Clin1 LCA2; FT-002 Clin1 X-linked retinitis pigmentosa; FT-004 Clin0 Hemophilia B; 4 add'l early stage products
About:
Frontera Therapeutics is developing cost-effective recombinant virus-based gene therapies across multiple disease areas. Using their APEX technology and manufacturing platform, Frontera is creating adeno-associated virus (AAV) gene expression systems to develop novel gene therapy products with quicker speed-to-market and lower cost. With their advanced technology, Frontera is building a pipeline that extends beyond monogenic diseases to indications in Ophthalmology, Hematology and Cardiovascular and Metabolic Diseases.
Jobs:
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com